Tempest Therapeutics, Inc. (TPST)
- Previous Close
7.83 - Open
7.89 - Bid 5.69 x 200
- Ask 9.51 x 200
- Day's Range
7.37 - 7.94 - 52 Week Range
5.36 - 49.27 - Volume
60,610 - Avg. Volume
62,723 - Market Cap (intraday)
26.086M - Beta (5Y Monthly) -2.28
- PE Ratio (TTM)
-- - EPS (TTM)
-19.50 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
103.00
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various cancers. The company's two clinical programs Amezalpat formerly PST-1120, an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha, which is in Phase III; and TPST-1495, a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, which is in Phase II. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
www.tempesttx.comRecent News: TPST
View More
Performance Overview: TPST
Trailing total returns as of 4/29/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TPST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TPST
View MoreValuation Measures
Market Cap
27.56M
Enterprise Value
12.66M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-56.43%
Return on Equity (ttm)
-182.35%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-41.84M
Diluted EPS (ttm)
-19.50
Balance Sheet and Cash Flow
Total Cash (mrq)
30.27M
Total Debt/Equity (mrq)
80.34%
Levered Free Cash Flow (ttm)
-19.08M